File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Systemic Therapy for Esophageal Squamous Cell Carcinoma

TitleSystemic Therapy for Esophageal Squamous Cell Carcinoma
Authors
KeywordsEsophageal squamous cell carcinoma
Chemotherapy
Target therapy
Immune checkpoint inhibitor
Issue Date2020
PublisherHumana.
Citation
Systemic Therapy for Esophageal Squamous Cell Carcinoma. In Lam, AK (Ed.), Esophageal Squamous Cell Carcinoma: Methods and Protocols, p. 321-333. New York, NY: Humana, 2020 How to Cite?
AbstractWith more understanding of the tumor biology, esophageal squamous cell carcinoma (ESCC) and adenocarcinoma are increasingly recognized as different disease entities and are managed with different treatment approaches. Most patients with ESCC need systemic treatment at some point of their disease course, but only until recently, the progress in systemic treatment has been relatively stagnant compared with its adenocarcinoma counterpart. Platinum-based regimens remain the standard of care, while taxanes have been increasingly used upfront and in later lines of treatment. The attempts to personalize treatment for ESCC with various target therapies have been futile. Immune checkpoint inhibitors are now coming into play with promising activity and potentials to combine with different treatment modalities. The current chapter overviews the systemic treatment for ESCC and highlights the recent development.
Persistent Identifierhttp://hdl.handle.net/10722/288369
ISBN
ISSN
2023 SCImago Journal Rankings: 0.399
Series/Report no.Methods in Molecular Biology ; 2129

 

DC FieldValueLanguage
dc.contributor.authorLam, KO-
dc.contributor.authorChan, WLW-
dc.contributor.authorSo, TH-
dc.contributor.authorKwong, DLW-
dc.date.accessioned2020-10-05T12:11:50Z-
dc.date.available2020-10-05T12:11:50Z-
dc.date.issued2020-
dc.identifier.citationSystemic Therapy for Esophageal Squamous Cell Carcinoma. In Lam, AK (Ed.), Esophageal Squamous Cell Carcinoma: Methods and Protocols, p. 321-333. New York, NY: Humana, 2020-
dc.identifier.isbn9781071603765-
dc.identifier.issn1064-3745-
dc.identifier.urihttp://hdl.handle.net/10722/288369-
dc.description.abstractWith more understanding of the tumor biology, esophageal squamous cell carcinoma (ESCC) and adenocarcinoma are increasingly recognized as different disease entities and are managed with different treatment approaches. Most patients with ESCC need systemic treatment at some point of their disease course, but only until recently, the progress in systemic treatment has been relatively stagnant compared with its adenocarcinoma counterpart. Platinum-based regimens remain the standard of care, while taxanes have been increasingly used upfront and in later lines of treatment. The attempts to personalize treatment for ESCC with various target therapies have been futile. Immune checkpoint inhibitors are now coming into play with promising activity and potentials to combine with different treatment modalities. The current chapter overviews the systemic treatment for ESCC and highlights the recent development.-
dc.languageeng-
dc.publisherHumana.-
dc.relation.ispartofEsophageal Squamous Cell Carcinoma: Methods and Protocols-
dc.relation.ispartofseriesMethods in Molecular Biology ; 2129-
dc.subjectEsophageal squamous cell carcinoma-
dc.subjectChemotherapy-
dc.subjectTarget therapy-
dc.subjectImmune checkpoint inhibitor-
dc.titleSystemic Therapy for Esophageal Squamous Cell Carcinoma-
dc.typeBook_Chapter-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailChan, WLW: winglok@hku.hk-
dc.identifier.emailSo, TH: sth495@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityChan, WLW=rp02541-
dc.identifier.authoritySo, TH=rp01981-
dc.identifier.authorityKwong, DLW=rp00414-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/978-1-0716-0377-2_24-
dc.identifier.pmid32056188-
dc.identifier.scopuseid_2-s2.0-85079361100-
dc.identifier.hkuros314727-
dc.identifier.hkuros317876-
dc.identifier.spage321-
dc.identifier.epage333-
dc.publisher.placeNew York, NY-
dc.identifier.issnl1064-3745-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats